Gumisad, Analiza .
HRN: 26-51-48 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/13/2025
CEFUROXIME 750MG (VIAL)
01/13/2025
01/20/2025
IV
300 Mg
Q8h
PCAP C
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes